Abstracts tagged "Biologic agents and systemic vasculitides"

Abstract Number: 1689 • 2019 ACR/ARP Annual Meeting
Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Polyarteritis Nodosa
Alice Canzian ¹, Omer Karadag ², Anne Contis ³, François Maurier ⁴, Silvia Sartorelli ⁵, Laure Denis ⁶, Sébastien Sanges ⁷, Claire de Moreuil ⁸, Cécile-Audrey Durel ⁹, Stéphane Durupt ¹⁰, Marie Jachiet ¹¹, Diane Rouzaud ¹², Carlo Salvarani ¹³, Franco Schiavon ¹⁴, Lorenzo Dagna ¹⁵, Fabrice Bonnet ¹⁶, David Jayne ¹⁷, Loic Guillevin ¹⁸ and Benjamin Terrier¹, ¹Cochin Hospital, Paris, France, ²Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey, ³Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France, Bordeaux, France, ⁴Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ⁵Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ⁶Clermont-Ferrand Hospital, Clermont-Ferrand, France, ⁷CHRU Lille, Lille, France, ⁸CHU Brest, Brest, France, ⁹Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁰Lyon Hospital, Lyon, France, ¹¹Saint Louis Hospital, Paris, France, ¹²Bichat Hospital, Paris, France, ¹³Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁴Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, Padova, Italy, ¹⁵Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ¹⁶CHU Bordeaux, Bordeaux, France, ¹⁷Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ¹⁸National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis of medium- and small-sized arteries, not associated with antineutrophil cytoplasmic antibodies (ANCA). Conventional treatments include…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].